Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Net Income for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 347.99% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 million through Dec 2025, down 20.35% year-over-year, with the annual reading at -$4.6 million for FY2025, 20.35% down from the prior year.
  • Net Income hit $1.5 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $5.1 million in Q1 2021 to a low of -$6.1 million in Q3 2021.
  • Historically, Net Income has averaged -$1.0 million across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in Net Income: soared 392.62% in 2023 and later tumbled 407.34% in 2025.
  • Year by year, Net Income stood at $1.0 million in 2021, then dropped by 12.22% to $912000.0 in 2022, then crashed by 347.37% to -$2.3 million in 2023, then surged by 73.49% to -$598000.0 in 2024, then soared by 347.99% to $1.5 million in 2025.
  • Business Quant data shows Net Income for ETON at $1.5 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.6 million in Q2 2025.